S100A9 as a potential novel target for experimental autoimmune cystitis and interstitial cystitis/bladder pain syndrome
S100A9 is an important pro-inflammatory and pathogenic molecule in IC/BPS and EAC. Targeting S100A9-initiated signalling pathways may offer a novel therapeutic strategy for IC/BPS.
Authors
- Mi Zhou (ORCID: https://orcid.org/0000-0001-7626-9768)
- Bishao Sun (ORCID: https://orcid.org/0000-0003-3962-5043)
- Xiangwei Wang (ORCID: https://orcid.org/0000-0001-8108-4979)
- Teng Yang (ORCID: https://orcid.org/0009-0000-4542-3814)
- Yang‐Wuyue Liu (ORCID: https://orcid.org/0000-0002-1394-5471)
- Benyi Li (ORCID: https://orcid.org/0000-0001-6242-5117)
- Chengfei Yang
- Zhao Jiang
- Ji Zheng
- Zhenxing Yang (ORCID: https://orcid.org/0000-0002-6260-6804)
- Shuang-Shuang Dai
Institutions
- Army Medical University (CN)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Qianjiang Central Hospital (CN)
- University of Kansas Medical Center (US)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Biomarker Research
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1186/s40364-025-00763-5
- Citations
- 4
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 3.22